bimekizumab · BIMEKIZUMAB 320 mg/2mL · Injection, Solution · Subcutaneous · UCB, Inc.
NDC 50474-0782-84 · 1 SYRINGE, GLASS in 1 CARTON / 2 mL in 1 SYRINGE, GLASS · BLA · View full market →
Just 2 companies supply this market — thin enough that a single exit would be felt immediately. Put together: worth watching — several of the pressures that precede supply trouble are present at once. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 5 quarters since 2024.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
sterile injectable · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is 3× that.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 4 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| UCB, Inc. | BIMEKIZUMAB 160 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| UCB, Inc. | BIMEKIZUMAB 320 mg/2mL | Jul 15, 2026 | Sep 3, 2026 |
| UCB Pharma S.A. | BIMEKIZUMAB 160 mg/mL | Jul 15, 2026 | Aug 12, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Bimzelx — NDC 50474-0782-84," retrieved September 3, 2026, https://drugdashboards.com/drug/50474078284.
Free to cite with attribution — see how the data is put together.